bioAffinity Technologies to present at H.C. Wainwright investment conference

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) said in an 8-K filing dated September 3, 2026 that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14 through 16, 2026.¹

According to the filing, Zannes' talk is expected to cover recent and upcoming milestones for the company, along with an update on commercial uptake of its CyPath Lung diagnostic test and progress on its broader diagnostic and therapeutic technology platform.¹

The company noted that institutional investors can register to attend the conference either virtually or in person at the Lotte New York Palace Hotel, and that registered attendees may request one-on-one meetings through the conference website.¹ A webcast of the presentation, both live and archived, will be available starting September 11 at a link the company provided.¹

The filing also disclosed bioAffinity's share structure as of September 2, 2026: the company reported 600,736 shares of common stock outstanding, with an aggregate market value of roughly $5.9 million based on that day's closing price on the Nasdaq Capital Market.¹

bioAffinity described itself in the release as a company focused on noninvasive diagnosis of early-stage cancer and other lung diseases, along with broad-spectrum cancer treatments.¹ Its lead product, CyPath Lung, is described as a noninvasive test that has demonstrated high sensitivity, specificity, and accuracy in detecting early-stage lung cancer.¹ The test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, which the filing identifies as a subsidiary of bioAffinity Technologies.¹